05.10.18

Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch

Source: Kala Pharmaceuticals

Kala Pharmaceuticals announced the following key commercial hires in preparation for the potential approval and launch of Inveltys, a twice-daily steroid eye drop in development for the treatment of inflammation and pain following ocular surgery:

  • Kathleen McCann Kline, Vice President of Marketing
  • James Patnoe, Vice President of Commercial Operations and Pricing
  • Carl Rennie, Executive Director of Account Management
  • Patrick Bedell, Executive Director of Trade and Alternate Channels
  • Lynette Zickl, Director of Commercial Analytics and Forecasting

“We are excited to welcome Kate, Jim, Carl, Pat and Lynette to Kala at such a pivotal time in our company’s history. We believe that the collective talent, leadership and seasoned industry experience of our new team members will greatly advance Kala’s evolution into a commercial organization,” Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals, said in a company news release. “As we prepare for the potential approval and launch of Inveltys, a product candidate that could be the first approved BID steroid eye drop for the treatment of inflammation and pain following ocular surgery, we will also continue to focus on advancing our other pipeline candidates, including KPI-121 0.25% for dry eye disease.”

Kala plans to continue growing its commercial organization in preparation for the launch of Inveltys, including hiring its own specialty ophthalmology sales force pending the potential approval of the new drug application (NDA) for Inveltys by the FDA. Kala’s NDA for Inveltys was accepted for review by the FDA in January 2018 and given a target action date under the Prescription Drug User Fee Act (PDUFA) of August 24, 2018.

Kathleen McCann Kline, Vice President of Marketing

Ms. Kline has joined Kala Pharmaceuticals as Vice President of Marketing. Most recently, she served as Vice President of Marketing for the Ophthalmology and Women’s Health divisions at Bausch and Lomb where she was instrumental in leading the strategic initiatives supporting numerous surgical and pharmaceutical franchises, including intraocular lenses, surgical equipment and the Loteprednol franchise. Previously, Ms. Kline held Director and Product Manager positions at Allergan Pharmaceuticals where her focus was on their ophthalmology brands, including Restasis and Refresh.

James Patnoe, Vice President of Commercial Operations and Pricing

Mr. Patnoe has joined Kala Pharmaceuticals as Vice President of Commercial Operations and Pricing. Previously, he served as Vice President of Sales Operations, Contracts and Pricing at Takeda Pharmaceuticals America, where he spent 10 years in roles of increasing responsibility, including Vice President of Managed Markets. Formerly, he worked for TAP Pharmaceuticals and held various sales and leadership positions, including Vice President of Managed Markets, Director of Sales Operations and National Account Sales Director.

Carl Rennie, Executive Director of Account Management

Mr. Rennie has joined Kala Pharmaceuticals as Executive Director of Account Management. Prior to Kala, he was the Director of National Accounts for Collegium Pharmaceuticals. Previously, he worked for Sunovion Pharmaceuticals (Sepracor) as Executive Director of Payer Markets and National Director of Corporate Accounts. Mr. Rennie served in the United States Army Medical Service Corps.

Patrick Bedell, Executive Director of Trade and Alternate Channels

Mr. Bedell has joined Kala Pharmaceuticals as Executive Director of Trade and Alternate Channels. Most recently, he was Senior Director of Trade and Alternate Channels for Collegium Pharmaceuticals. Prior to Collegium, he worked in several commercial roles at Sunovion Pharmaceuticals (Sepracor), including Executive Director of Trade and Alternate Channels.

Lynette Zickl, Director of Commercial Analytics and Forecasting

Ms. Zickl has joined Kala Pharmaceuticals as Director of Commercial Analytics and Forecasting. Previously, she was Head of Insights and Analytics for scPharmaceuticals, where she led the Commercial Analytics and Operations build-out and helped the company transition from Series A to a publicly-traded company. Prior to scPharmaceuticals, she held commercial analytics roles at Shire and Cubist Pharmaceuticals.

Related Content